10-Q: Schrodinger Reports Q2 2025 Results: Revenue Up, Losses Narrow

Schrodinger, Inc. reported a 16% increase in total revenues for Q2 2025, narrowing its net loss and achieving positive operating cash flow, driven by strong software growth and a significant upfront payment from a new drug discovery collaboration.

Summary

• Total revenues for the three months ended June 30, 2025, increased by 16% to $54.8 million, up from $47.3 million in the same period last year.
• Software products and services revenue grew by 15% to $40.5 million in Q2 2025, primarily due to a 38% increase in hosted software subscriptions and new software contribution revenue.
• Drug discovery revenue increased by 19% to $14.2 million in Q2 2025, largely due to the Novartis collaboration and progress in existing programs.
• Net loss for Q2 2025 improved to $43.2 million, compared to a net loss of $54.0 million for Q2 2024.
• For the six months ended June 30, 2025, net cash provided by operating activities was $91.9 million, a significant improvement from $93.0 million used in the prior year period, primarily due to cash collections from the Novartis collaboration.
• The company initiated dosing in Phase 1 clinical trials for SGR-2921 (CDC7 inhibitor) and SGR-3515 (Wee1/Myt1 inhibitor), with initial data anticipated in Q4 2025 for both.
• Initial clinical data for SGR-1505 (MALT1 inhibitor) in B-cell malignancies showed it was well-tolerated with preliminary clinical activity, including a 22% overall response rate.
• A research collaboration and license agreement with Novartis Pharma AG, entered in November 2024, included an initial upfront payment of $150.0 million received in January 2025, with potential for up to $2.272 billion in total milestone payments.
• A restructuring on May 19, 2025, reduced the workforce by approximately 60 employees (7% of full-time staff), expected to result in $3 million in charges in FY2025 and reduce operating expenses by approximately $30 million annually.
• As of June 30, 2025, cash, cash equivalents, restricted cash, and marketable securities totaled $462.3 million.

Sentiment

Score: 7

Explanation: The company demonstrated strong financial improvements with narrowed losses and a significant positive shift in operating cash flow, driven by increased revenues and a major collaboration upfront payment. Progress in multiple clinical programs and strategic cost-cutting measures are positive. However, the company still faces substantial operating losses, declining gross profit margins in key segments, and inherent high risks associated with drug discovery and competitive markets.

Positives

• Total revenues increased by 16% year-over-year in Q2 2025, demonstrating continued growth.
• Software products and services revenue saw a healthy 15% increase, driven by strong growth in hosted software subscriptions (38% increase).
• Drug discovery revenue increased by 19%, bolstered by the new Novartis collaboration and progress in existing programs.
• Net loss significantly narrowed to $43.2 million in Q2 2025 from $54.0 million in Q2 2024, indicating improved financial performance.
• Operating activities generated $91.9 million in cash for the six months ended June 30, 2025, a substantial positive shift from a net cash outflow in the prior year.
• The company maintains a strong liquidity position with $462.3 million in cash, cash equivalents, restricted cash, and marketable securities as of June 30, 2025.
• SGR-1505 received Fast Track designation from the FDA for Waldenstrom macroglobulinemia in June 2025, and preliminary clinical activity was observed in Phase 1 trials.
• SGR-2921 received Fast Track designation in July 2024 and Orphan Drug designation in January 2025 for relapsed or refractory AML.
• The expanded collaboration with Eli Lilly and Company and the new agreement with Novartis Pharma AG provide significant potential for future milestone payments and royalties.
• The initiative with the Bill & Melinda Gates Foundation, funded by $19.5 million in grants, aims to expand the computational platform for toxicity prediction, addressing a critical drug discovery challenge.

Negatives

• Gross profit decreased by 17% in Q2 2025 to $26.2 million, down from $31.3 million in Q2 2024.
• Cost of revenues for software products and services increased significantly by 82% in Q2 2025, outpacing revenue growth in this segment.
• Drug discovery segment reported a gross loss of $1.4 million in Q2 2025, a decline from a gross profit of $3.1 million in Q2 2024.
• On-premise software revenue decreased by 16% in Q2 2025 due to the timing of multi-year renewals.
• Professional services revenue decreased by 12% in Q2 2025.
• Drug discovery contribution revenue decreased by 35% in Q2 2025.
• The company continues to incur significant operating losses and expects to do so for several more years.
• The May 2025 restructuring involved a reduction of approximately 7% of the workforce, indicating a need for cost control measures.

Risks

• The company has a history of significant operating losses and expects to incur losses over the next several years.
• Inability to increase software sales, drug discovery collaboration revenue, or successfully develop and commercialize drug products could lead to insufficient revenues for profitability.
• Quarterly and annual results may fluctuate significantly due to various factors, including customer renewal rates, timing of large contracts, and milestone achievements.
• Existing customers may not renew licenses, buy additional solutions, or may renew at lower prices, adversely affecting operating results.
• A significant portion of revenues are from life sciences industry customers, making the company vulnerable to adverse factors affecting this industry.
• The markets in which the company operates are highly competitive, potentially affecting business and operating results if not effectively competed against.
• There is no guarantee of a return on investment in drug discovery collaborations, as clinical drug development is lengthy, expensive, and uncertain.
• The focus on using the computational platform for drug discovery may not result in commercially viable products for the company or its collaborators.
• The company may not successfully identify, discover, or develop product candidates and may fail to capitalize on programs with greater commercial opportunity.
• The company has very limited experience in clinical development, which may adversely impact the success of advancing its programs.
• Additional capital will likely be required to fund operations, and inability to raise it on acceptable terms could harm the business.
• Conducting successful clinical trials requires sufficient patient enrollment, which may be difficult to identify and recruit.
• Reliance on third parties (CROs) to conduct clinical trials carries risks of unsatisfactory performance or missed deadlines.
• Outcomes of preclinical studies and early clinical trials may not predict success in later clinical trials, and results may not satisfy regulatory requirements.
• Failure to comply with obligations under existing or future intellectual property licenses could lead to loss of important intellectual property rights.
• Inability to obtain, maintain, enforce, and protect patent protection could allow competitors to develop similar technologies and products.
• Internal information technology systems or those of third-party vendors may fail or suffer security breaches, compromising sensitive information and exposing the company to liability.
• Future success depends on the ability to retain key executives and attract, retain, and motivate qualified personnel.
• Pursuing multiple business strategies and expanding development/regulatory capabilities may lead to difficulties in managing growth and disrupt operations.
• Executive officers, directors, and principal stockholders have the ability to influence matters submitted to stockholders for approval.
• Actual operating results may differ significantly from guidance provided.
• Climate change-related risks and legal/regulatory responses could negatively impact the business.
• Changes in tax laws or their implementation/interpretation could adversely affect business and financial condition.
• The ability to use Net Operating Losses (NOLs) and research and development tax credit carryforwards may be subject to limitations.
• International operations subject the company to potentially adverse tax consequences.
• Acquisitions could divert management attention, result in dilution, and disrupt operations.
• Operations may be interrupted by natural disasters or catastrophic events at primary facilities.
• Lawsuits to protect or enforce patent or other intellectual property rights could be expensive, time-consuming, and unsuccessful.
• Third parties may initiate legal proceedings alleging infringement of their intellectual property rights.
• Inability to protect the confidentiality of trade secrets could harm business and competitive position.
• If product candidates obtain regulatory approval, additional competitors could enter the market with generic versions.
• The regulatory approval process is expensive, time-consuming, and uncertain, potentially preventing or delaying commercialization.
• Failure to obtain marketing approval in foreign jurisdictions would impair revenue generation.
• Accelerated development pathways may not lead to expedited approval or approval at all.
• Orphan drug exclusivity may not be obtained or may not prevent competing products.
• Terms of approvals and ongoing regulation could require substantial resource expenditure and limit manufacturing/marketing.
• Government investigations of alleged violations of law could require significant resources and generate negative publicity.
• Disruptions at the FDA and other government agencies could hinder timely guidance and approval.
• Current and future legislation may increase the difficulty and cost to obtain reimbursement for products.
• Changes in and uncertainty surrounding U.S. and international trade policies, particularly with respect to China, may adversely impact business.
• Employees, independent contractors, consultants, and vendors may engage in misconduct or improper activities, leading to significant liability and reputational harm.
• The price of common stock is volatile and fluctuates substantially, potentially resulting in losses for stockholders.
• Broad discretion in the use of cash, cash equivalents, and marketable securities may not be effective.
• No cash dividends are anticipated in the foreseeable future, making capital appreciation the sole source of gain for stockholders.
• Sales of a substantial number of shares of common stock in the public market could significantly drop the market price.
• Operating as a public company incurs increased costs and requires substantial management time for compliance initiatives.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Provisions in corporate charter documents and Delaware law could make an acquisition more difficult and prevent attempts to replace directors/management.
• The certificate of incorporation designates Delaware courts as the sole and exclusive forum for certain actions, potentially discouraging lawsuits.

Future Outlook

The company anticipates continued investment in its proprietary drug discovery programs and computational platform, expecting operating expenses to increase substantially in the foreseeable future. It believes existing cash, cash equivalents, and marketable securities will fund operations and capital expenditures for at least the next 24 months. The company plans to utilize these funds primarily for software and drug discovery activities, with a strategy to advance proprietary programs through internal development, co-development collaborations, or out-licensing to maximize commercial opportunities. The company expects drug discovery revenue to fluctuate due to the uncertain timing of milestone achievements and dependence on collaborator decisions.

Management Comments

• We expect to meet with the FDA to discuss the recommended Phase 2 dose for SGR-1505 by the end of 2025.
• We are exploring strategic opportunities to advance the clinical development of SGR-1505.
• We anticipate reporting initial data from the SGR-2921 Phase 1 trial in the fourth quarter of 2025.
• We anticipate reporting initial data from the SGR-3515 Phase 1 trial in the fourth quarter of 2025.
• The reduction in workforce and cost reductions being implemented are expected to reduce operating expenses by approximately $30 million on an annualized basis.

Industry Context

The company operates in the highly competitive and rapidly evolving biopharmaceutical and materials science industries, leveraging a physics-based computational platform for molecular discovery. The industry is seeing increasing adoption of computational methods, including AI, for drug discovery. The company's strategy of combining software licensing with proprietary drug discovery and collaborations positions it to capitalize on these trends, but also exposes it to intense competition from established pharmaceutical companies, biotechnology firms, and new entrants utilizing AI. Regulatory changes, such as those impacting drug pricing and clinical trial diversity, continue to shape the landscape, adding complexity and uncertainty to drug development and commercialization.

Comparison to Industry Standards

• The company's computational platform aims to identify more promising molecules and accelerate drug discovery compared to traditional methods, as evidenced by past collaborations like Nimbus Therapeutics, which led to a significant acquisition by Takeda Pharmaceuticals.
• The collaboration with Novartis Pharma AG, with potential milestones up to $2.272 billion, is a substantial agreement comparable to major industry partnerships, indicating strong validation of the company's platform.
• The company's approach of leveraging its platform for both software licensing and proprietary drug discovery is a hybrid model, differentiating it from pure-play software vendors (e.g., BIOVIA, Certara) and traditional biotech companies, allowing for diversified revenue streams and synergistic benefits.
• The company's proprietary drug candidates (SGR-1505, SGR-2921, SGR-3515) are advancing into clinical trials, placing it among a cohort of innovative biotech firms, though it faces competition from other companies with similar targets (e.g., AbbVie, HotSpot Therapeutics for MALT1 inhibitors; Zentalis Pharmaceuticals for Wee1 inhibitors).

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently subject to any material legal proceedings.

Related Party Transactions

• Paid consulting fees of $109,000 (Q2 2025) and $218,000 (six months ended June 30, 2025) to a member of its board of directors.
• Recognized $11,000 (Q2 2025) and $20,000 (six months ended June 30, 2025) in revenue from a grant issued by the Bill & Melinda Gates Foundation (a stockholder) for licenses and services to third-party organizations.
• Recognized $212,000 (Q2 2025) and $711,000 (six months ended June 30, 2025) in drug discovery contribution revenue from an agreement with the Bill & Melinda Gates Foundation for accelerating drug discovery in women's health.
• Recognized $4,513,000 (Q2 2025) and $8,357,000 (six months ended June 30, 2025) in software contribution revenue from agreements with the Bill & Melinda Gates Foundation to fund the expansion of the computational platform for toxicity prediction.
• No revenue was recognized from the agreement with Gates Ventures, LLC (an entity under common control with a beneficial owner of voting securities) during Q2 2025 or the six months ended June 30, 2025.

Stakeholder Impact

• **Shareholders:** Improved net loss and positive operating cash flow could be viewed favorably, potentially increasing investor confidence. However, continued overall losses and gross margin pressure in drug discovery remain concerns. The ATM program could lead to future dilution.
• **Employees:** The May 2025 workforce reduction of approximately 60 employees indicates job insecurity for some, but the overall restructuring aims to improve operational efficiency and long-term stability. Continued investment in R&D and platform development suggests ongoing opportunities for scientific and technical staff.
• **Customers (Software):** Increased hosted software revenue indicates strong adoption and satisfaction. The initiative to predict toxicity could lead to more robust software solutions, benefiting drug discovery customers. However, a decrease in on-premise software revenue and professional services suggests shifts in customer engagement or project timing.
• **Collaborators (Drug Discovery):** New and expanded collaborations (Novartis, Lilly) demonstrate continued interest in the company's platform and potential for shared success. The advancement of proprietary drug candidates to clinical trials could lead to more valuable partnerships and licensing opportunities.
• **Creditors:** The improved cash position and positive operating cash flow enhance the company's ability to meet its financial obligations, reducing credit risk.

Next Steps

• Meet with the FDA by the end of 2025 to discuss the recommended Phase 2 dose for SGR-1505.
• Report initial data from the Phase 1 clinical trial of SGR-2921 in the fourth quarter of 2025.
• Report initial data from the Phase 1 clinical trial of SGR-3515 in the fourth quarter of 2025.
• Continue to invest in and develop the computational platform and software solutions.
• Continue research and development efforts for proprietary drug discovery programs.
• Conduct preclinical studies and initiate and conduct clinical trials for product candidates.
• Prepare and make regulatory submissions for product candidates.
• Maintain, expand, enforce, defend, and protect intellectual property.
• Hire additional software engineers, programmers, sales and marketing, and other personnel to support the software business and other commercial operations.
• Hire additional clinical, quality control, regulatory, chemical, manufacturing and control and other scientific personnel.
• Add operational, financial, and management information systems and personnel to support operations as a public company.
• Evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on financial condition and results of operations, with impact to be included in Q3 2025 financial statements.

Key Dates

Recommendation

While Schrodinger, Inc. demonstrated significant financial improvements with narrowed losses and a strong positive shift to operating cash flow, driven by a substantial upfront payment from Novartis, the underlying gross profit decline and continued overall operating losses in the drug discovery segment warrant caution. The company's proprietary drug pipeline is advancing, with multiple candidates in Phase 1 trials and key designations, which is positive for long-term potential. However, the inherent high risks of clinical development, intense competition, and the recent workforce reduction suggest ongoing operational challenges. The stock's volatility and the need for potential future capital raises also add uncertainty. A 'hold' recommendation reflects the balance between promising long-term growth potential from its unique platform and collaborations, and the near-to-medium term financial pressures and execution risks in a highly competitive and capital-intensive industry.

Keywords

Drug Discovery, Computational Platform, Software Solutions, Biopharmaceutical, Life Sciences, MALT1 Inhibitor, CDC7 Inhibitor, Wee1/Myt1 Inhibitor, Clinical Trials, SEC Filing, Biotechnology, Pharmaceutical, AI in Drug Discovery, Orphan Drug, Fast Track Designation, Novartis Collaboration, Eli Lilly Collaboration, Gates Foundation, Financial Results, Corporate Restructuring